OraPro-COVID-19 - iosBio
Alternative Names: COVID-19 vaccine - iosBioLatest Information Update: 28 Apr 2024
Price :
$50 *
At a glance
- Originator Stabilitech Biopharma
- Developer iosBio
- Class COVID-19 vaccines; Gene therapies; Viral vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in United Kingdom (PO, Capsule)
- 30 Sep 2020 Stabilitech Biopharma is now called iosBio
- 30 Sep 2020 Stabilitech Biopharma plans a clinical trial for COVID-19 infections in the US and Europe in first quarter of 2021